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Abstract: 
A new combined gas chromatography and mass spectrometry (GC–MS) method has been 
developed suitable for the urine sample treatment in aqueous phase with ethyl chloroformate 
(ECF) derivatization agents. The method has been extensively optimized and validated over a 
broad range of different compounds and urine samples. Analysis of test metabolite derivatives, 
containing spiked standards, or rat urine exhibited acceptable linearity, satisfactory intra-batch 
precision (repeatability) and stability, relative standard deviations (R.S.D.) less than 10 and 15% 
within 48 h, respectively. The quantification limits were 150–300 pg on column for most 
metabolites. Recovery of several representative compounds, at different concentrations, ranged 
from 70 to 120%, with R.S.D. better than 10% for rat urine. We were able to generally eliminate 
potentially confounding variables such as medium complexity, different urea concentrations, 
and/or derivatization procedure variability. Metabonomic profiling of 1,2-dimethylhydrazine 
(DMH)-induced precancerous colon rat urine using GC–MS with ECF derivatization was 
performed to evaluate the proposed method. The analytical variation of the method was smaller 
than the biological variation in the rat urine samples, proving the suitability of the method to 
analyze differences in the metabonome of a living system with perturbed metabolic network. 
Thus, the proposed GC–MS analytical method is reliable to analyze a large variety of 
metabolites and can be used to investigate human pathology including disease onset, progression, 
and mortality. 
 
Article: 
INTRODUCTION 
Systems biology, commonly involving genomics, proteomics, and metabonomics, is emerging as 
a vital component of life science research [1]. The integration of these “-omics” are likely to 
provide novel insights and understanding of life's complexity [2]. Metabonomic, which is 
generally defined as the multi-parametric metabolic responses of a living system to 
pathophysiological stimuli or genetic modification [3], is an effective tool for toxicological 
studies on pharmacologically active agents, for disease biomarker screening, and for 
characterization of biological pathways [4-8]. To accomplish these types of screens, 
metabonomic analysis focuses on metabolites, small molecules less than 1000 Da, in a single 
cell, biofluids, or tissue. Utilizing widely ascribed multivariate data analysis methods such as 
principal component analysis (PCA) [9], partial least square (PLS) [10], and artificial neural 
networks (ANN) [11,12], we are able to elucidate significant differences and locate the possible 
“biomarkers” responsible for such variance within a huge number of endogenous metabolites. 
 
Metabonomic studies require sensitivity, quantifiable data, and robustness of analytical 
methodology, which generally employ such techniques as nuclear magnetic resonance (NMR) 
[4,7,13-16], high-performance liquid chromatography–mass spectrometry (LC–MS, and LC–
MS–MS) [17-21], capillary electrophoresis–mass spectrometry (CE–MS) [12,22,23], and gas 
chromatography–mass spectrometry (GC–MS) [24-28]. However, none of these analytical 
techniques could truly gather all the endogenous metabolites present in the biological samples 
but combinations of analytical techniques facilitate a more comprehensive analysis [29]. In this 
study, we “harvest” the information contained in the rat urine metabolite fragmentations detected 
with a GC–MS method consisting of electron impact (EI) ionization and single quadrupole mass 
analyzer. This method provides the necessary data to identify possible metabolites present, which 
can be further validated if appropriate standards are utilized. Since many metabolites are unstable 
at separation temperatures or not volatile, derivatization prior to GC–MS detection is a common 
prerequisite. Unlike trimethylsilyl derivatization agents which only work in nonaqueous phase, 
ECF is reactive in aqueous medium, less expensive, and less time-consuming [26-28] during the 
derivatization process. To our knowledge, a GC–MS method with ECF derivatization technique 
has not been previously used in the metabonomics context, and therefore we embarked on a 
study to determine if the methodology was appropriate for analysis of endogenous metabolites 
from dimethyl hydrazine (DMH)-induced, precancerous colon rat's urine [30]. The new GC–MS 
procedure with ECF derivatization has been optimized to effectively capture and analyze a range 
of metabolites involving organic acids, amines, amino acids, fatty acids, and amino-alcohols, 
without water exclusion during derivatization. 
 
EXPERIMENTAL 
Materials and methods 
Ethyl chloroformate (ECF), pyridine, anhydrous ethanol, sodium hydroxide, chloroform, and 
anhydrous sodium sulfate were analytical grade from China National Pharmaceutical Group 
Corporation (Shanghai, China). l-2-chlorophenylalanine (Shanghai Intechem Tech. Co. Ltd., 
China) was used as an internal quality standard. Standards (Table 1) used for method 
optimization and validation were obtained from Sigma-Aldrich (St. Louis, MO, USA) and 
prepared in the ultrapure water from a Milli-Q system (Millipore, USA). Urine samples were 
collected from male Wistar healthy rats and DMH-induced (1,2-dimethylhydrazine; Sigma-
Aldrich) precancerous colon rats (n = 6 for each group, 150 ± 10 g) and stored at −20 °C. 
 
 
 
 
 
 
 
 
 
Table 1: Linearity and quantification limit of standards 
Compound Linear range 
(μg mL−1)a 
n r2b Quantification limit 
    pg on columnc S/N ratiod 
Amino acids 
 l-Alanine 0.25–20 8 0.9991 150 50 
 l-Glycine 0.25–20 8 0.9997 150 40 
 l-Valine 0.25–20 8 0.9992 150 33 
 l-Leucine 0.25–20 8 0.9997 150 49 
 l-Isoleucine 0.25–20 8 0.9983 150 14 
 l-Threonine 0.25–20 8 0.9946 150 9.8 
 l-Proline 0.25–20 8 0.9993 150 50 
 l-Aspartic acid 0.25–20 8 0.9908 150 63 
 l-Methionine 0.25–20 8 0.9989 150 20 
 l-glutamine acid 1–20 6 0.9992 150 9.8 
 l-Phenylalanine 0.25–15 7 0.9960 150 38 
 l-Cysteine 0.25–20 8 0.9979 150 24 
 l- Lysine 0.5–20 7 0.9832 600 9.7 
 l-Tyrosine 0.25–20 8 0.9946 150 14 
 Asparagine 1–20 7 0.9992 300 18 
 Glutamine 5–20 4 0.9799 3000 17.2 
  
Amines 
 n-Butylamine 0.5–40 8 0.9951 300 98 
 Putrescine 0.25–15 7 0.9929 150 30.8 
 Tyramine 0.5–40 8 0.9966 300 23 
 Dopamine 1–40 7 0.9814 300 10.2 
  
Organic acids 
 Fumaric acid 0.5–20 7 0.9951 150 42 
 Malate 0.25–20 8 0.9992 150 17 
 Succinate 0.25–20 8 0.9947 150 533 
 Butenedioic acid 0.5–20 7 0.9964 150 45 
 Phenylacetic acid 0.25–20 8 0.9976 150 9.2 
aEach standard stock solution of test compounds was carefully prepared in the distilled water (1 mg mL−1) and stored at −4 °C. The spiked 
standard solution was accordingly obtained by the addition of each aliquot of stock solution above involving 100 μL of each amino acid, 100 μL 
of each organic acid, and 200 μL of each amine. So the spiked standards concentration was about 30 μg mL−1 for organic acids or amino acids, 
and 60 μg mL−1 for amines. Different volumes of the spiked standard solution were diluted into 600 μL of water for linear range determination. 
bRegression coefficients were calculated for linearity ranging at the concentration listed here. 
cQualification limit (pg on column) is the lowest calibration standard injected with a S/N ratio ≥9. 
dS/N ratio calculation was carried out to display the peak-to-peak values by TurboMass software. 
 
Derivatization 
Each 600-μL aliquot of standard mixture or diluted urine sample (urine: water = 1:1, v/v) was 
added to a screw-top glass tube. After adding 100 μL of l-2-chlorophenylalanine (0.1 mg mL−1), 
400 μL of anhydrous ethanol, and 100 μL of pyridine to the urine sample, 50 μL of ECF was 
added for first derivatization at 20.0 ± 0.1 °C. The pooled mixtures were sonicated at 40 kHz for 
60 s. Subsequently, extraction was performed using 300 μL of chloroform, with the aqueous 
layer pH carefully adjusted to 9–10 using 100 μL of NaOH (7 mol L−1). The derivatization 
procedure was repeated with the addition of 50 μL ECF into the aforementioned products. After 
the two successive derivatization steps, the overall mixtures were vortexed for 30 s and 
centrifuged for 3 min at 3000 rpm. The aqueous layer was aspirated off, while the remaining 
chloroform layer containing derivatives were isolated and dried with anhydrous sodium sulfate 
and subsequently subjected to GC–MS analysis. 
 
GC–MS analysis 
The derivatized extracts were analyzed with a PerkinElmer gas chromatograph coupled with a 
TurboMass-Autosystem XL mass spectrometer (PerkinElmer Inc., USA). A 1-μL extract aliquot 
of the extracts was injected into a DB-5MS capillary column coated with 5% diphenyl cross-
linked 95% dimethylpolysiloxane (30 m× 250 μm i.d., 0.25-μm film thickness; Agilent J&W 
Scientific, Folsom, CA) in the split mode (3:1). Either the injection temperature or the interface 
temperature was set to 260 °C; and the ion source temperature was adjusted to 200 °C. Initial GC 
oven temperature was 80 °C; 2 min after injection, the GC oven temperature was raised to 
140 °C with 10 °C min−1, to 240 °C at a rate of 4 °C min−1, to 280 °C with 10 °C min−1 again, 
and finally held at 280 °C for 3 min. Helium was the carrier gas with a flow rate set at 
1 mL min−1. The measurements were made with electron impact ionization (70 eV) in the full 
scan mode (m/z 30–550). 
 
Data analysis 
All the GC–MS raw files were converted to CDF format via DataBridge (PerkinElmer Inc., 
USA), subsequently processed by the XCMS toolbox (http://metlin.scripps.edu/download/) using 
XCMS's default settings with the following exceptions: xcmsSet (full width at half-maximum: 
fwhm = 4; S/N cutoff value: snthresh = 8, max = 20), group (bw = 5) [31,32]. The resulting table 
(TSV file) was exported into Matlab software 7.0 (The MathWorks, Inc.), where normalization 
was performed prior to multivariate analyses. The resulting three dimensional matrix involving 
peak index (RT-m/z pair), sample names (observations), and normalized peak area percent was 
introduced into Simca-P 11.0 Software package (Umetrics, Umeå, Sweden), which utilizes 
principal components analysis (PCA) to display the metabolic information visually. Additionally, 
the majority of the metabolites detected were identified by Turbomass 4.1.1 software 
(PerkinElmer Inc., USA) coupled with commercially available compound libraries: NIST, Wiley, 
and reference compounds available. 
 
RESULTS 
Derivatization procedure 
As previously published [28], ECF derivatization is favored because of two advantages. First, 
ECF derivatization proceeds in the aqueous medium and thus does not necessarily remove water 
before reaction, which facilitates batch preparation and improved reproducibility. Secondly, two-
step derivatization protocols have satisfactory derivatization efficiencies and enhanced data 
collection, i.e. more peaks were detected in urine samples, and each peak area of the 25 
representative test compounds belonging to different chemical classes (amino acids, organic 
acids, and amines) were significantly expanded (data now shown). Notably, adjusting the pH 
with NaOH is crucial for the further derivatization probably because these molecules are more 
soluble and reactive in the aqueous medium [33]. Also, derivatization time, temperature, and 
GC–MS parameters (see Section 2) were chosen not solely upon the 25 reference compounds but 
also in consideration of the urine samples. 
 
Linearity and quantification limit 
The linearity of response was determined by using spiked standards at different concentrations 
ranging from 0.25 to 20 μg mL−1 for amino acids or organic acids and from 0.5 to 40 μg mL−1 for 
amines. A calibration curve for each test compound was adjusted using an internal standard. For 
most of the compounds investigated, the coefficients of determination (r-squares) generally 
approached 1.000 (Table 1). Exceptions were compounds such as glutamine, l-lysine, putrescine 
and dopamine, which had nonlinear regression at lower or higher concentrations. The final 
adjusted r-squares were achieved by excluding such data. 
 
In this paper, we determined each compound's quantification limit by analyzing the signal-to-
noise ratio (S/N) provided by TurboMass interface, where the greatest height of the signal range 
above the mean noise value is divided by the variance. From Table 1, all the S/N values are 
higher than 9.0, allowing the individual calculation of each compound's quantification limit. 
Occasionally, the actual quantification limit was lower than the lowest spiked concentration, 
which had a higher S/N value. In this case, the lowest spiked concentration was used as the 
quantification limit, e.g. succinate. 
 
Reproducibility and stability 
We used both the spiked standard solution and urine sample from a typical healthy rat to 
investigate reproducibility. After the correction with internal standard, the relative standard 
deviations (R.S.D.) of peak area for each standard spiked and standards (endogenous 
metabolites) detected in rat urine were comparable, R.S.D. below 10%. The results were repeated 
by two different operators. However, several derivatives such as fumaric acid, glutamine, and 
succinate could not be detected in the urine predominately due to the detection limits. 
Additionally, standard compounds with varying physical and chemical properties were selected 
for the stability assay. For most spiked compounds, the R.S.D. were better than 10% within 36 h 
and less than 15% within 48 h (Fig. 1). l-Glutamine acid and asparagine were suspected to be 
unstable metabolites because of RSDs higher than 15%, after 60 h. The GC–MS sensitivity 
appeared to decrease after about 60 samples (∼48 h); therefore, each batch analysis was 
performed within 2 days. 
 
Recovery of standards in rat urine 
To further validate our methodology to analyze complex endogenous metabolites, each 300-μL 
aliquot of 20, 50, 100, and 200 μg mL−1 of 14 standard solutions were spiked to 300 μL in pooled 
urine, prior to ECF-derivatization. Importantly, these compounds were specifically selected from 
different species with various characteristics, e.g. fumaric acid, an organic acid, was not detected 
in the urine, while amino acids, typical of l-leucine, was quantitatively detected in a relative 
higher amount. In general, extraction recovery was calculated through an adjusted linear curve, 
and the mean recovery of all these compounds with different concentrations ranged from 70 to 
120% with R.S.D. better than 10% (Table 2). Considering the environment variation, each 
300 μL of the test compounds was mixed with 300 μL urine from a healthy male volunteer. 
However, the results are comparable to rat urine (data not shown). In addition, urea did not 
disrupt our derivatization or extraction, suggesting urea does not react with the derivatization 
reagent. 
 
Figure 1: Repeatability of the test compounds from the spiked standard solution (1 μg mL−1) (n = 6) and detected 
from the urine samples (n = 6); stability of the test compounds added (n = 12). aNot detected in standard 
solution; bnot detected in the urine sample; cunstable compounds, R.S.D. of the corrected response was slightly 
higher than 15 after 60-h determination. 
 
 
Table 2: Recovery of several typical standardsa 
Compounds Recovery (%)b 
 Average R.S.D. 
n-Butylaminec 79.3 5.1 
Tyraminec 74.1 6.0 
Dopaminec 84.1 5.5 
l-Valined 83.4 5.1 
l-Leucined 74.5 3.0 
l-Isoleucined 82.7 3.2 
Malatee and f 76.2 4.6 
Fumaric acide and f 80.2 7.0 
l-Cysteined 99.9 9.2 
l-Tyrosined 82.9 2.6 
l-Prolined 80.0 6.0 
Asparagined 110.9 4.9 
l-Aspartic acidd 110.5 2.4 
l-Phenylalanined 74.1 1.1 
l-Glutamine acidd and g 88.3 6.3 
l-Methionined and f 110.5 5.4 
aThe standards were screened for recovery calculation based on their various characteristics and concentration in urine.    bMean Recovery was 
obtained by 12 determinations (three parallel samples at four different concentrations) with an internal standard.    cAmines group.   dAmino acids 
group.   eOrganic acids group.   fNot commonly detected in a typical urine sample.   gUnstable metabolites. 
 
 
Application 
DMH-induced precancerous colon rat model tested the potential application of the GC–MS 
method, with ECF derivatization, for the body fluid analysis. We analyzed rat urine samples 
obtained from healthy or DMH-treated rats (n = 6 for each group) (DMH was IP given twice 
with one week interval. Samples were collected seven weeks after treatment). Using our 
optimized GC–MS analysis protocol, we identified about 200–250 different urine metabolites, 
with 87 of them present in the library or confirmed via standard compounds (data not shown). 
The R.S.D. of the added internal standards were less than 5% and the mean recovery was about 
10%, indicating the GC–MS method was reproducible. In the Fig. 2, the total ion chromatograms 
(TIC) of urine samples from two groups (the healthy control versus DMH-induced precancerous 
colon group) are illustrated. Visual examination of the TICs shows a major difference with each 
other, typically in the zoomed range. The GC–MS data were processed via XCMS software prior 
to PCA. PCA scores plot (Fig. 3) of GC–MS data describes the general differences between two 
different groups at the end point of the study. To obtain a vivid view in the results from 
multivariate data analysis, univariate plots were made. In these error-bar plots (Fig. 4), the mean 
and standard deviation were plotted for each group. Such a plot may help explore the nature of 
biological disturbance reflected by these latent biomarkers. For instance, the mean concentration 
of tryptophan is higher in the DMH-induced group than in the healthy group, indicating that the 
biological pathway related to tryptophan may be disturbed to some extent, while the 
concentration of 4-hydroxybenzeneacetic acid is somewhat higher in the healthy group than in 
the drug group. The mechanism of DMH-induced pathological change may be elucidated based 
on the up- or down-regulated metabolic pathways reflected by these biological alterations. 
 
 
Figure 2: Full scan GC–MS TIC of typical urine samples from different group (DMH-induced vs. healthy control). 
 
Figure 3: PCA scores plot from the analysis of DMH-induced precancerous colon rats (▿) and healthy control rats (▵). 
 
 
Figure 4: Univariate up- or down-regulation error-bar plots for potential biomarkers responsible for DMH-induced 
precancerous colon rats. An asterisk (*) represents the mean value, and the error bars. 
DISCUSSION 
The goal of metabonomic study is to analyze as many metabolites as possible from biological 
fluids like urine, serum, semen, or tissue. Such a noninvasive approach can facilitate a better 
understanding of global biological functions and can be help in disease detection. However, 
development of a comprehensive analytical metabonomic methodology with high reproducibility 
and stability is difficult due to the technique's extreme sensitivity and possibility of misleading 
results generated from analytical variations. Combined gas chromatography and mass 
spectrometry (GC–MS) is one of the most commonly used techniques because of its simplicity, 
stability and reproducibility. 
 
A new GC–MS method has been developed suitable for the urine sample treatment in aqueous 
phase with ECF derivatization agents. The method has been extensively optimized and validated 
over a broad range of different compounds and urine samples. Metabolites of interest in urine 
samples can generally be classified into three major groups: amino acids, organic acids, and 
amines. We detected metabolites over a large, linear dynamic range (0.25–20 μg mL−1), and the 
detection limits were low (∼150 pg on column), with the exception of a few compounds such as 
glutamine and l-lysine which become detectable at 1–2 μg mL−1 with the current single 
quadrupole mass analyzer. 
 
Most samples for metabonomics studies are large scale batch processing and thus the 
measurements can be time intensive. Inter- or intra-batch analysis performed within short period 
of time, i.e. 48 h, should be reasonably stable and reliable. Mean recovery of different 
concentrations was 70–120%, which indicated reasonable derivatization efficiency. The R.S.D. 
of mean recovery for these compounds was satisfactory, at lower than 10%, suggesting that the 
different concentration of urea in the samples exerted little interference with the detection of 
other metabolites. 
 
XCMS package for metabolite profiling involved three important algorithms: peak detection, 
peak matching, and retention time alignment algorithms. This provided a comparable function 
for peak resolution. Since the GC–MS system elution rate was fast, with sharp peaks, the full 
width at half-maximum (fwhm) was set at 4. The S/N cutoff value (snthresh = 8) was based on 
the previously mentioned quantification limits. 
 
The analytical variation of the method was small, compared with the biological variation in the 
rat urine samples, proving the suitability of the method to analyze differences in the metabonome 
of a living system with perturbed metabolic network. Thus, the proposed GC–MS methodology 
is reliable to analyze a large variety of metabolites and can be used to investigate human 
pathology including disease onset, progression, and mortality. 
 
CONCLUSION 
We described a convenient, quantitative and precise analytical method using GC–MS with ECF 
derivatization with a very large application range for the analysis of all metabolites from cells, 
body fluids, and tissue. The method has been extensively optimized and validated over a broad 
range of different compounds and urine samples, and practically used for metabolic profiling of 
urine samples from DMH-induced model rats. It appeared that such a metabonomic technique is 
able to delineate the characteristic metabolite expression pattern for a global analysis of a living 
system with disturbed regulatory network because of its capability and reproducibility in the 
quantitative analyses of several classes of metabolites, primarily involving amino acids, organic 
acids, and amines. Based on its simplicity, robust performance and wide applicability, this 
method is expected to play an important role in the metabonomic study and systems biology. 
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